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Introduction
In mammals, 2 different types of adipose tissues coexist; these 
exert specific functions in the context of energy balance regula-
tion. White adipose tissue (WAT) is the main site for the organ-
ism’s energy storage and is a highly active endocrine organ able 
to regulate energy homeostasis by affecting the activity of other 
organs, including the brain (1–4). Conversely, brown adipose tis-
sue (BAT) is specialized in thermogenesis and energy dissipation 
(5, 6). The confirmation of the presence of BAT in human subjects 
has stimulated interest in the potential clinical relevance of BAT 
activation for the treatment of obesity (7, 8).
Adipose tissue can undergo dynamic remodeling, including 
quantitative and qualitative alterations of adipose tissue–resident 
cells. In obesity, changes in number and size of adipocytes have 
been extensively described (9). New insights have also revealed 
that a cell subpopulation of WAT, called beige or brite adipocytes, 
under certain stimuli are able to express uncoupling protein 1 
(Ucp1) and are engaged in thermogenesis, a process known as adi-
pose tissue browning (10). Human BAT shares more similarities 
with mouse beige cells than classical brown adipocytes (11, 12), 
which is therapeutically relevant, since human BAT thermogene-
sis can be activated by β3 adrenergic receptor agonists (13). Recent 
insights have suggested that alternatively activated macrophages 
in adipose tissue act as a source of catecholamines, contributing 
to adaptive thermogenesis and browning of WAT (14–17). Howev-
er, the latest investigations have questioned this proposition (18, 
19). Thus, understanding the mechanisms involved in the devel-
opment of functional beige cells is a key element in finding novel 
therapeutic targets for tackling obesity.
The endocannabinoid system plays a critical role in energy 
balance via several mechanisms, including regulation of adipo-
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CB1 deletion in adipocytes prevents DIO. Ati-CB1–KO and Ati-
CB1–WT mice were monitored while being maintained on SD and 
HFD for 12 weeks, respectively. In order to exclude confounding 
factors of Cre recombinase expression per se on the metabolic 
phenotype, the body weight growth curve of heterozygous Adipoq-
CreERT2tg /+ mice was analyzed. As these mutant mice were previ-
ously shown to have no alteration in body weight under SD con-
ditions as compared with WT (35), we determined whether HFD 
could differentially affect AdipoqCreERT2tg /+ mice and their WT 
littermates. No differences in body weight were observed between 
genotypes (Supplemental Figure 2A), further validating the suit-
ability of this genetic tool.
Under SD, Ati-CB1–KO mice displayed a significantly reduced 
body weight gain compared with WT (Figure 1A). Under HFD, WT 
mice became obese, while Ati-CB1–KO littermates were resistant 
to DIO (Figure 1B). Accordingly, Ati-CB1–KO displayed reduced 
total adiposity under both SD and HFD (Figure 1, C and D). No sig-
nificant differences in body weight were observed between CB1–/– 
mice (herein referred to as Total-CB1–KO) and Ati-CB1–KO mice 
under HFD (Figure 1E), suggesting that CB1 deletion in adipocytes 
is sufficient to protect against DIO. Plasma insulin, leptin, and glu-
cose levels were not significantly different between Ati-CB1–KO 
and WT littermates under SD (Figure 1, F and G, and Supplemen-
tal Figure 2B). HFD exposure increased these parameters in Ati-
CB1–WT mice, but it failed to alter them in Ati-CB1–KO mice (Fig-
ure 1, F and G, and Supplemental Figure 2B). Plasma adiponectin 
levels were significantly increased in Ati-CB1–KO as compared 
with WT mice, independently of the diet (Figure 1H). In contrast, 
we did not observe a decrease in adiponectin levels in Ati-CB1–WT 
under this HFD as compared with SD, most likely due to the mild 
increase in caloric fat content of the HFD we used. Adiponectin is 
an adipokine with insulin-sensitizing functions (36, 37). Accord-
ingly, Ati-CB1–KO displayed increased insulin sensitivity as com-
pared with Ati-CB1–WT both in SD and HFD, as assessed by the 
insulin tolerance test (Supplemental Figure 2, C and D). HFD-fed 
Ati-CB1–WT mice were also characterized by increased plasma 
free-fatty acid, LDL, and triglyceride levels (Figure 1, I and J, and 
Supplemental Figure 2E). However, no signs of dyslipidemia were 
observed in Ati-CB1–KO exposed to HFD (Figure 1, I and J, and 
Supplemental Figure 2E). Similarly, no signs of hepatic steatosis 
were observed in HFD-fed Ati-CB1–KO mice (Supplemental Fig-
ure 2F). Obesity is a chronic low-inflammatory condition (38). 
Plasma levels of the inflammatory markers plasminogen-activator 
inhibitor 1 (PAI1) and IL-6 were increased in HFD-fed Ati-CB1–
WT as compared with SD-fed WT. Ati-CB1–KO had reduced PAI1 
levels as compared with Ati-CB1–WT on SD, and these levels were 
not altered by HFD (Figure 1K). Similarly, HFD did not affect plas-
ma IL-6 levels in Ati-CB1–KO mice, but these values were instead 
increased in WT littermates (Supplemental Figure 2G). Obesity is 
also characterized by an overactive endocannabinoid system (39, 
40). Indeed, plasma levels of the endocannabinoid anandamide 
(AEA) (Figure 1L), but not of 2-arachidonoyl glycerol (data not 
shown), were increased in Ati-CB1–WT on HFD as compared with 
SD; this increase was absent in Ati-CB1–KO.
CB1 deletion in adipocytes leads to fat depot–specific alterations 
and lowers energy storage capacity. Lack of adipocyte CB1 led to 
profound modifications in adipocyte morphology and physiolo-
cyte physiology (20–22). Activation of the cannabinoid receptor 
type-1 (CB1) stimulates adipogenesis and lipogenesis, leading to 
impaired mitochondrial function in diet-induced obesity (DIO) 
(20, 23, 24). CB1 activation in mouse and human WAT reduces 
mitochondrial mass and function by downregulation of PPARγ 
coactivator 1α (Ppargc1a), while genetic and pharmacological 
blockade of CB1 function increases mitochondrial biogenesis 
by enhancing Ppargc1a expression (24, 25). Accordingly, body 
weight loss induced by chronic administration of CB1 antago-
nists is largely due to increased energy expenditure (EE) and 
consequent activation of lipolysis and fatty acid oxidation (21, 
26–28). However, the therapeutic use of CB1 antagonists, such as 
rimonabant, is hampered by serious side effects, which include 
depression and anxiety, primarily caused by the action of this 
drug in the brain (29, 30). Nonetheless, peripherally restricted 
CB1 antagonists were developed as a safer alternative and have 
been shown to alleviate obesity (31–33). However, the exact sites 
and mechanisms of action leading to the observed effects are 
currently poorly defined. Thus, to clearly determine the role of 
CB1 in adipose tissue physiology and its relevance as a target of 
treatment, we generated an adipocyte-specific CB1-KO mouse 
line and demonstrated that adipocyte CB1 plays a crucial role 
in controlling adipocyte physiology and in regulating the energy 
balance of the entire organism.
Results
Generation of adipocyte-specific CB1-deficient mice. We generat-
ed adipocyte-specific CB1-KO mice by crossing CB1-floxed mice 
(34) with transgenic AdipoqCreERT2 mice (35), which express Cre 
recombinase under the regulatory sequences of the adiponec-
tin gene. Tamoxifen-induced recombination at 5 weeks of age 
led to adipocyte-specific CB1-deficient mice (named Ati-CB1–
KO). Genomic DNA analysis revealed that CB1 deletion required 
tamoxifen treatment and occurred specifically in epididymal fat 
(EF), subcutaneous fat (SF), and BAT Ati-CB1–KO mice (Supple-
mental Figure 1, A–C; supplemental material available online with 
this article; https://doi.org/10.1172/JCI83626DS1), while CB1 
deletion was excluded from nonadipose tissues, such as hypo-
thalamus, soleus muscle, and liver (Supplemental Figure 1B). In 
addition, lack of recombination in various brain areas relevant for 
CB1-mediated control of energy homeostasis (anterior olfactory 
nucleus, nucleus accumbens, hypothalamus) was shown by ana-
lyzing β-galactosidase staining in the double-transgenic mouse 
line AdipoqCreERT2;ROSA26LacZ (35) (Supplemental Figure 
1D). As revealed by quantitative reverse-transcriptase PCR (RT- 
qPCR), standard diet–fed (SD-fed) (11% of calories from fat) Ati-
CB1–KO mice displayed a strong reduction in CB1 mRNA levels in 
EF (70%–80%), SF (60%–70%), mesenteric fat (MF) (70%–80%), 
and BAT (40%) at the age of 20 weeks (Supplemental Figure 1E) as 
compared with their WT littermate controls (named Ati-CB1–WT). 
CB1 mRNA levels were also reduced when animals were exposed 
to a high-fat diet (HFD) (40% of calories from fat) for 12 weeks 
(Supplemental Figure 1F). Immunohistochemical analysis showed 
the absence of CB1 protein in adipocytes of Ati-CB1–KO mice 
(Supplemental Figure 1G), and no genotype differences in CB1 
mRNA levels were found in nonadipose tissues, including brain, 
liver, and soleus muscle (Supplemental Figure 1H).
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Ati-CB1–KO (Figure 2E). MF of SD- and HFD-fed Ati-CB1–KO dis-
played an upregulation of Pparg and Adipoq mRNAs as compared 
with Ati-CB1–WT littermates (Figure 2, C and F), while Cebpa was 
increased only in SD (Figure 2C). The upregulation of Adipoq was 
confirmed by immunofluorescence analysis (Supplemental Fig-
ure 3A). In MF, no significant differences were observed in Lep, 
Fasn, and Acaca mRNA levels, independently from the diet (Fig-
ure 2, C and F). Thus, adipocyte CB1 is an important regulator of 
WAT differentiation and adiponectin production. These features 
were paralleled by histological modifications. SD- and HFD-fed 
Ati-CB1–KO mice did not show cellular hypertrophy in EF and 
MF as compared with Ati-CB1–WT mice (Figure 2G and Supple-
mental Figure 3, B and C). Furthermore, histological analysis of 
gy. Interestingly, these changes were fat-depot specific. EF from 
SD- and HFD-fed Ati-CB1–KO displayed reduced mRNA levels of 
Pparg, CAAT/enhancer binding protein α (Cebpa), and adiponec-
tin (Adipoq) (Figure 2, A and D), suggesting an impaired differenti-
ation state of EF. Accordingly, EF from Ati-CB1–KO mice displayed 
decreased leptin (lep), fatty acid synthase (Fasn), and acetyl coen-
zyme A carboxylase α (Acaca) (latter significant only under HFD) 
mRNA levels. Similar changes were also observed in SF of SD-fed 
Ati-CB1–KO mice (Figure 2B). However, under HFD, SF adipo-
cytes from Ati-CB1–KO did not display differences in mRNA levels 
of Pparg, Cebpa, and Adipoq as compared with WT (Figure 2E). In 
contrast, Lep mRNA levels were downregulated and, surprisingly, 
Fasn and Acaca mRNA levels were upregulated in SF of HFD-fed 
Figure 1. Adipocyte CB1 deletion prevents DIO and metabolic dysregulation. (A) Body weight growth curves of Ati-CB1–KO (n = 21) and Ati-CB1–WT (n = 24) 
littermates on SD. Tamoxifen-induced recombination occurred for 5 days at 5 weeks of age (arrow). Tam, tamoxifen. (B) Body weight growth curves of Ati-
CB1–WT (n = 22) and Ati-CB1–KO (n = 19) mice on HFD. Tam-induced recombination occurred for 5 days at 5 weeks of age (arrow). The switch from SD to HFD 
was at the beginning of week 7. (C) 3D visualization (ventral view) of skeleton (white) and total adipose tissue (red) from in vivo micro-CT images of Ati-CB1–
WT and Ati-CB1–KO mice (19 weeks of age) on SD and HFD, respectively. (D) Quantification of total fat content (as percentage of total mouse volume) by in 
vivo micro-CT analysis in Ati-CB1–WT and Ati-CB1–KO mice on SD and HFD, respectively. (E) Comparison of body weight growth curves of Ati-CB1–KO (n = 19) 
mice and Total-CB1–KO (n = 8) mice on HFD. (F–L) Plasma profiles of Ati-CB1–WT (n = 4–9) and Ati-CB1–KO (n = 4–8) on both diet treatments (at 19 weeks of 
age). Data are shown as mean ± SEM. *P < 0.05; #P < 0.01; †P < 0.001. Two-way ANOVA (A, B, E); Student’s t test (D); 1-way ANOVA (F–L).
Downloaded from http://www.jci.org on November 2, 2017.   https://doi.org/10.1172/JCI83626
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 1 5 1jci.org   Volume 127   Number 11   November 2017
Figure 2. CB1-dependent gene expression profile in adipocytes is 
depot specific. (A–F) Gene expression analysis (relative units) of 
Pparg, Cebpa, Lep, Fasn, Adipoq, and Acaca in EF, SF, and MF from 
Ati-CB1–WT and Ati-CB1–KO on SD (WT, n = 5–9; KO, n = 5–8), and 
HFD (WT, n = 5–8; KO, n = 5–6). (G) Representative images of EF, SF, 
and MF from Ati-CB1–WT and Ati-CB1–KO on both SD and HFD. H&E 
staining. Scale bars: 100 μm. (H–K) Gene expression analysis (relative 
units) of Cox8b, Ucp1, Ppargc1a, and Adrb3 in SF from Ati-CB1–WT 
(n = 4–7) and Ati-CB1–KO (n = 4–7) on both SD and HFD. (L) Electron 
microscopy of SF from Ati-CB1–WT and Ati-CB1–KO on both SD and 
HFD. Scale bar: 1 μm. mito, mitochondrium; lp, lipid droplet. (M–O) 
Gene expression analysis (relative units) of Cox4i2, Ucp1, and Adrb3 
in BAT from Ati-CB1–WT (n = 6) and Ati-CB1–KO (n = 6–8) on both SD 
and HFD. Data are shown as mean ± SEM. *P < 0.05; #P < 0.01;  
†P < 0.001 vs. WT, Student’s t test.
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SF, and BAT of Ati-CB1–KO on HFD were elevated as compared 
with WT. Furthermore, based on the observation of increased 
Adrb3 mRNA levels in SF (Figure 2K), we investigated whether 
β3 adrenergic receptor response is altered in WAT from Ati-CB1–
KO. Indeed, the stimulation of in vivo lipolysis induced by the 
selective β3 adrenergic receptor agonist CL316243 was sustained 
in Ati-CB1–KO as compared with Ati-CB1–WT control mice under 
HFD (Supplemental Figure 4G).
The upregulation of thermogenic markers and the increased 
adipose NE turnover and NE concentration suggest that Ati-
CB1–KO have increased energy dissipation. Accordingly, EE was 
higher in Ati-CB1–KO than in WT littermates on HFD (Figure 3F), 
whereas ambulatory activity was not different between genotypes 
(Figure 3G). The increased EE in Ati-CB1–KO mice was further 
confirmed by analysis of covariance (ANCOVA), in which the pos-
sible bias on EE analysis caused by differences in body weight is 
excluded (46). As shown, linear regression between mouse body 
weight and EE clearly demonstrates increased EE in Ati-CB1–KO 
mice as compared with their WT littermates under HFD (Supple-
mental Figure 4H). Similar results were found when we analyzed 
resting EE (REE) (Supplemental Figure 4I).
Increased abundance of alternatively activated macrophages in 
Ati-CB1–KO adipose tissue. Next, we aimed at understanding the 
mechanistic underpinnings of the remodeling observed in adipose 
tissues of Ati-CB1–KO mice under HFD. Gene expression of the 3 
catecholamine-synthesizing enzymes, tyrosine hydroxylase (Th), 
dopamine β hydroxylase (Dbh), and dopa decarboxylase (Ddc), 
were increased in whole EF, SF, and BAT in Ati-CB1–KO (Sup-
plemental Figure 5A). Based on recent findings that alternative 
activation of macrophages (i.e., M2 polarization) contributes to 
adaptive thermogenesis and browning of WAT (14–17), whereby 
M2 macrophages act as a local source of catecholamines (14–17), 
we analyzed this process in Ati-CB1–WT and Ati-CB1–KO mice in 
HFD. We found significant increases in mRNA levels of 2 M2 mark-
ers analyzed (Mrc1, Clec10a) in all fat tissues investigated (EF, SF, 
BAT) in Ati-CB1–KO as compared with Ati-CB1–WT mice (Figure 
3, H–J). These increases were further underlined at the protein lev-
el by flow cytometry analysis (Figure 3K, and Supplemental Fig-
ure 5B), wherein the median fluorescence intensities (MFI) for the 
M2 markers CD206 (mannose receptor C type 1, encoded by the 
Mrc1 gene) and CD301 (C-type lectin domain family 10 member 
A, encoded by the Clec10a gene) in EF were significantly increased 
in Ati-CB1–KO as compared with WT controls (Figure 3K).
In order to analyze whether these adipose tissue macrophages 
(ATMs) are able to synthesize NE, gene and protein expression 
analyses were performed in WAT-derived CD11b+F4/80+ stromal 
vascular cells, as defined by 2 well-described canonical markers 
of macrophages (Supplemental Figure 5C). First, we quantified 
gene expression of 3 enzymes (Th, Dbh, and Ddc) involved in cat-
echolamine synthesis in CD11b+F4/80+ ATMs from Ati-CB1–KO 
and WT mice on HFD (Figure 3L). We found that Th and Ddc 
mRNA levels were significantly increased in FACS-sorted ATMs 
(CD11b+F4/80+ cells) from Ati-CB1–KO mice as compared with 
control WT littermates (Figure 3L), which is in congruence with 
gene expression data obtained from whole adipose tissue (Sup-
plemental Figure 5A). We also observed that alternatively acti-
vated macrophage markers (Mrc1, Clec10a) were upregulated in 
SF from SD- and HFD-fed Ati-CB1–KO revealed the presence of 
adipocytes with reduced cell size and lipid content and increased 
multilocular aspect (Figure 2G) (41). Consistent with these histo-
logical features, mRNA levels of the mitochondrial markers cyto-
chrome c oxidase VIIIb (Cox8b), cytochrome c oxidase IV isoform 
2 (Cox4i2) (only on SD), and mitochondrial transcription factor A 
(Tfam) were significantly upregulated in SF of Ati-CB1–KO as com-
pared with Ati-CB1–WT (Figure 2H and Supplemental Figure 3, D 
and E). Notably, mRNA levels of Ucp1, Ppargc1a, and β3 adrenergic 
receptor (Adrb3) were significantly increased in SF from Ati-CB1–
KO on HFD as compared with Ati-CB1–WT (Figure 2, I–K). Also, 
mRNA levels of deiodinase iodothyronine type II (Dio2) were 
strongly upregulated in SF of Ati-CB1–KO as compared with Ati-
CB1–WT mice, independently of the diet (Supplemental Figure 
3F). mRNA levels of the fatty acid elongase 3 (Elovl3), an enzyme 
whose expression positively correlates with the amount of BAT 
(42), were decreased in SF of Ati-CB1–WT on HFD, but increased 
in Ati-CB1–KO mice as compared with Ati-CB1–WT mice on SD 
(Supplemental Figure 3G). Electron microscopic analysis showed 
that mitochondria from SF of Ati-CB1–KO were larger in size and 
had increased cristae content as compared with Ati-CB1–WT, 
independently of the diet (Figure 2L). This was associated with an 
increase in UCP1 protein levels in SF of Ati-CB1–KO (Supplemen-
tal Figure 3H). Similarly, BAT of Ati-CB1–KO also had increased 
mRNA levels of Cox4i2 (only on SD), Ucp1, and Adrb3 (Figure 2, 
M–O). Brown adipocytes are able to synthesize and release adi-
ponectin (43). Accordingly, Adipoq mRNA was upregulated in BAT 
from Ati-CB1–KO on HFD (Supplemental Figure 3I).
CB1 deletion in adipocytes affects energy homeostasis. Daily calor-
ic intake was significantly reduced in Ati-CB1–KO as compared 
with Ati-CB1–WT littermates under both SD and HFD (Figure 3A), 
and this decrease was associated with increased mRNA levels of 
the anorectic neuropeptide proopiomelanocortin (Pomc) in hypo-
thalamus (Supplemental Figure 4A), while mRNA levels of other 
anorectic/orexigenic transcripts (neuropeptide Y [Npy]; cocaine- 
and amphetamine-regulated transcript [Cartpt]; pro-melanin- 
concentrating hormone [Pmch]) did not differ between the 2 gen-
otypes (Supplemental Figure 4B). Pomc-expressing neurons in the 
arcuate nucleus of hypothalamus are one of the main targets of 
leptin action (44). Suppressor of cytokine signaling 3 (Socs3) plays 
an important role in the inhibition of leptin receptor signaling, and 
its expression leads to cellular leptin resistance (45). Accordingly, 
Socs3 mRNA levels were significantly increased in the hypothal-
amus of Ati-CB1–WT on HFD (Supplemental Figure 4C), while 
Ati-CB1–KO expressed Socs3 mRNA levels comparable to those 
observed under SD, suggesting preserved leptin sensitivity under 
HFD. In order to study the role of decreased food intake in the lean 
phenotype of Ati-CB1–KO on HFD, we performed a pair-feeding 
experiment (Figure 3B). The body weight increase in Ati-CB1–WT 
mice was unaffected by the reduced food intake, suggesting that 
the lean phenotype of the Ati-CB1–KO mice was primarily due to 
feeding-independent mechanisms.
Increased expression of Dio2 mRNA in SF (Supplemental 
Figure 3F) and of Adrb3 mRNA in SF and BAT of Ati-CB1–KO 
(Figure 2, K and O) implies possible changes in peripheral nor-
epinephrine (NE) signaling. Indeed, NE turnover rate (Figure 3, 
C–E) and NE concentration (Supplemental Figure 4, D–F) in EF, 
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Figure 3. CB1 deletion in adipocytes affects caloric intake and EE and promotes alternative macrophage activation. (A) Daily caloric intake (in kJ) of 
Ati-CB1–WT (SD fed, n = 11; HFD fed, n = 21) and Ati-CB1–KO mice (SD fed, n = 17; HFD fed, n = 27) on SD and HFD. (B) Pair-feeding experiment. Body weight 
curves of Ati-CB1–WT (n = 8) and Ati-CB1–KO (n = 13) on HFD. Tissue NE turnover in EF (C), SF (D), and BAT (E) from Ati-CB1–WT (n = 3) and Ati-CB1–KO 
mice (n = 4) on HFD. (F) EE in Ati-CB1–WT (n = 16) and Ati-CB1–KO mice (n = 13) on HFD. (G) Ambulatory activity during indirect calorimetry recording in 
Ati-CB1–WT (n = 16) and Ati-CB1–KO (n = 13) on HFD. (H–J) Gene expression analysis (relative units) of markers for alternatively activated macrophages 
(Mrc1, Clec10a) in EF, SF, and BAT from Ati-CB1–WT and Ati-CB1–KO mice on HFD (n = 11–12). (K) Protein markers for alternatively activated macrophages 
(CD206 and CD301) were monitored by flow cytometry in EF from Ati-CB1–WT and Ati-CB1–KO mice on HFD (n = 11–12). (L) Gene expression (relative units) 
of the catecholamine-synthesizing enzymes (Th, Dbh, Ddc) and alternatively activated macrophage markers (Mrc1, Clec10a) in CD11b+F4/80+-sorted ATMs 
from WAT of Ati-CB1–WT (n = 6–11) and Ati-CB1–KO (n = 5–11) mice on HFD. Dbh mRNA levels were measured by ddPCR analysis. (M) TH protein levels were 
measured by flow cytometry in CD11b+F4/80+-sorted ATMs (left) and CD301+ cells (M2 macrophages, right) in WAT from Ati-CB1–WT (n = 9) and Ati-CB1–KO 
(n = 9) mice on HFD. Data are shown as mean ± SEM. *P < 0.05; #P < 0.01; †P < 0.001, Student’s t test (A, C–E, H–M); 2-way ANOVA (B, F, G).
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sorted ATMs from mutant mice (Figure 3L). Importantly, Th gene 
expression levels in isolated ATMs were very low, but detectable 
by real-time PCR, while negative control samples never gave a sig-
nal (data not shown). In order to confirm this finding, we applied a 
second gene expression quantification method in an independent 
batch of sorted ATMs, using the more sensitive digital droplet 
PCR (ddPCR) system (Supplemental Figure 6A). In fact, we could 
only measure Dbh gene expression in sorted ATMs by ddPCR 
analysis (Supplemental Figure 6B). ddPCR analysis revealed 
almost 3-fold increased Th mRNA levels in ATMs in comparison 
with Dbh (Supplemental Figure 6, A and B). This marginal expres-
sion of Th and Dbh in ATMs was specific, since we could not detect 
any single copy in negative control samples among independent 
experiments using the ddPCR method (Supplemental Figure 6C). 
Next, using flow cytometry analysis, we measured TH protein lev-
els in adipose tissue CD11b+F4/80+ cells and found enhanced TH 
protein levels in Ati-CB1–KO mice as compared with WT controls 
(Figure 3M and Supplemental Figure 5D). Furthermore, support-
ing the mRNA expression data, similarly increased TH protein 
levels were found in adipose tissue CD301+ M2 macrophages after 
deletion of CB1 in adipocytes (Figure 3M and Supplemental Fig-
ure 5D). We tested the selectivity of the anti-TH antibody used in 
Th-deficient mouse spleen samples (Supplemental Figure 5E).
Finally, we performed TH immunostaining anatomical stud-
ies in adipose tissue. First, immunoperoxidase staining of TH in 
adipose tissue showed an increased number of TH+ parenchymal 
fibers in BAT and SF from Ati-CB1–KO mice (Supplemental Fig-
ure 7), besides confirming an increased sympathetic tone in the 
mutant mice. Strikingly, double-fluorescence confocal analysis 
showed that CD206+ cells were in a tight anatomical proximity to 
TH+ sympathetic nerve fibers in both BAT and SF (Supplemental 
Figure 8). The close proximity between M2 macrophage cellular 
extensions and sympathetic nerve terminals was particularly evi-
dent in BAT, where we found a more pronounced increase in nor-
adrenergic parenchymal nerve fibers than in SF.
In summary, the abundance of alternatively activated mac-
rophages along with an enhanced sympathetic innervation was 
found to be increased in adipose tissues of Ati-CB1–KO mice. In 
addition, we clearly demonstrated that ATMs express the cate-
cholamine-synthesizing machinery and that the absence of CB1 
in adipocytes increased both mRNA and protein levels of TH in 
ATMs and in the alternatively activated M2 macrophages.
Lean phenotype of Ati-CB1–KO at thermoneutral conditions. We 
next investigated whether a lean phenotype in Ati-CB1–KO could be 
observed at thermoneutrality (i.e., at 30°C) in the absence of chron-
ic thermal stress. Animal housing conditions (22°C) demand extra 
energy, increasing total metabolism of the mice (50%–60% above 
basal) for the maintenance of body temperature (47). Interestingly, 
the same body weight difference between WT and KO groups was 
present at both 22°C and 30°C temperatures (Supplemental Fig-
ure 9A). Under thermoneutral conditions (30°C), both genotypes 
reduced food consumption as compared with at 22°C (Supplemen-
tal Figure 9B), in order to adjust to reduced adaptive thermogene-
sis. Accordingly, expression of thermogenic markers (Ucp1, Elovl3) 
in BAT was blunted in Ati-CB1–WT and Ati-CB1–KO mice at 30°C 
in comparison with Ati-CB1–WT at 22°C (Supplemental Figure 9C). 
Nevertheless, mRNA levels of markers for mitochondrial biogene-
sis (Ppargc1a, Tfam), M2 macrophage polarization (Clec10a, Mrc1), 
and NE production (Ddc) in SF were significantly increased in Ati-
CB1–KO housed at thermoneutrality as compared with control WT 
littermates (Supplemental Figure 9D), although to a lower extent 
than at 22°C. Similarly, M2 macrophage polarization and NE syn-
thesis machinery were enhanced in BAT of Ati-CB1–KO as com-
pared with WT (Supplemental Figure 9E). Altogether, given that at 
thermoneutrality, SNS-induced BAT thermogenesis is most likely 
diminished, these experiments suggest that enhanced M2 macro-
phage polarization makes a major contribution to the lean pheno-
type of Ati-CB1–KO at thermoneutrality.
Adipocyte reprogramming precedes the appearance of body weight 
differences. In order to determine whether adipocyte reprogram-
ming is in causative relation with the loss of CB1 in adipocytes or 
whether it is merely an effect of the lack of obesity, we character-
ized SD-fed Ati-CB1–KO mice at 2 weeks after tamoxifen-induced 
genetic deletion of CB1 in adipocytes, when body weight differenc-
es had not yet occurred (Figure 4A). At this time, Ati-CB1–KO mice 
showed a strong reduction in CB1 mRNA levels in EF, SF, and BAT 
(Figure 4B). At the histological level, the deletion of CB1 promot-
ed a profound remodeling in adipocytes in SF (Figure 4C) with-
out alterations in adipocyte cell size in EF (Figure 4D). Interest-
ingly, we observed strongly increased lipogenic (Fasn, Acaca) and 
lowered Lep gene expression in EF (Figure 4E), indicating a late 
differentiation status of adipocytes, similar to what was observed 
in adipocyte cell cultures (48, 49). This delayed differentiation in 
EF was associated with increased levels of alternatively activat-
ed macrophages and catecholamine production (Figure 4, F–I, 
and Supplemental Figure 10). Deletion of CB1 in SF led to WAT 
browning (Figure 4, C and J) and increase of mitochondrial mark-
er (Cox4i2) in BAT (Figure 4K). Together, these experiments indi-
cate that the loss of CB1 function in adipocytes leads to a strong 
remodeling of the different adipose tissue depots, preceding the 
emergence of body weight differences, implying that the effects 
observed after CB1 loss are of primary cause and not secondary to 
the lack of DIO.
Reversal of obesity after inducible CB1 inactivation in adipocytes. 
To evaluate whether adipocyte CB1 deletion can reverse the con-
dition of preexisting obesity, we induced adipocyte CB1 inactiva-
tion in DIO mice. Mice were fed with a super-HFD (SHFD) (60% 
of calories from fat) for 12 weeks to reach severe obesity, and CB1 
deficiency was induced in 16-week-old SD-fed and SHFD-fed 
animals (named Ati-CB1–KO–TAO, where TAO indicates tamox-
ifen after obesity). Without tamoxifen treatment, WT and KO 
mice developed DIO under SHFD (Figure 5A). The injection of 
tamoxifen induced a strong reduction of CB1 mRNA levels in EF 
(70%–80%), SF (70%–80%), MF (60%), and BAT (50%–70%) in 
both SD- and SHFD-fed Ati-CB1–KO–TAO as compared with their 
WT littermates, as analyzed at 22 weeks of age (Supplemental 
Figure 11, A and B). Adipocyte-specific CB1 deletion induced at 16 
weeks of age in SD-fed Ati-CB1–KO–TAO did not cause significant 
changes in body weight and fat mass (Figure 5A and Supplemental 
Figure 11C), while adipocyte-specific CB1 deletion in SHFD-fed 
obese Ati-CB1–KO–TAO mice reduced body weight (Figure 5B) 
and the amount of EF and SF (Supplemental Figure 11D). The his-
tology of adipocytes from Ati-CB1–KO–TAO showed the presence 
of multilocular adipocytes within SF, a visible decreased adipocyte 
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more, plasma levels of PAI1 and IL-6 were significantly decreased 
in Ati-CB1–KO–TAO as compared with Ati-CB1–WT–TAO on SHFD 
and were similar to levels observed in SD (Figure 5, G and H). The 
reversal of obesity in Ati-CB1–KO–TAO was also associated with 
significantly improved glucose homeostasis and insulin sensitiv-
ity (Figure 5I). Finally, also in this model of the reversal of obesi-
ty, CB1 loss promoted M2 polarization, as detected by increased 
expression of Mrc1 and Clec10a in EF and SF (Figure 5J).
size in EF, and a lack of lipid accumulation in BAT (Supplemental 
Figure 11E). Decreased body weight in Ati-CB1–KO–TAO was also 
associated with lowered fasting blood glucose levels as compared 
with Ati-CB1–WT–TAO, suggesting improved glucose homeostasis 
(Figure 5C). In addition, Ati-CB1–KO–TAO on SHFD had reduced 
plasma insulin and leptin levels as compared with Ati-CB1–WT–
TAO (Figure 5, D and E), while plasma adiponectin levels were 
significantly increased in Ati-CB1–KO–TAO (Figure 5F). Further-
Figure 4. CB1 deletion in adipocytes 
promotes alternatively activated mac-
rophages and remodeling of adipose 
tissue preceding body weight changes. 
(A) Body weight of 7-week-old SD-fed 
Ati-CB1–WT (n = 13) and Ati-CB1–KO 
mice (n = 10) 2 weeks after tamoxi-
fen-induced CB1 deletion in adipocytes. 
(B) Relative CB1 mRNA levels are 
strongly decreased in EF, SF, and BAT 
from 7-week-old Ati-CB1–KO (n = 9–12) 
mice as compared with WT controls  
(n = 8–9) on SD. (C) Representative 
images of EF, SF, and BAT from 
Ati-CB1–WT and Ati-CB1–KO on SD. 
H&E staining. Scale bar: 100 μm. (D) 
Quantification of adipocyte cell size 
(arbitrary units) in EF from Ati-CB1–WT 
(n = 3) and Ati-CB1–KO (n = 3). (E) Gene 
expression analysis (relative units) in 
EF of markers of adipocyte differenti-
ation (Pparg, Cebpa) and lipogenesis 
(Fasn, Acaca) and of adipokines (Lep, 
Adipoq) (n = 9). (F) Gene expression 
analysis (relative units) of alternatively 
activated macrophages (Mrc1, Clec10a) 
in EF (n = 9). (G) Protein analysis of 
markers for alternatively activated 
macrophages (CD206 and CD301) was 
monitored by flow cytometry in EF 
from Ati-CB1–WT (n = 13) and Ati-CB1–
KO (n = 13) on SD. (H) Gene expression 
(relative units) of catecholamine- 
synthesizing enzymes (Th, Dbh, Ddc) 
in whole EF from Ati-CB1–WT (n = 3–8) 
and Ati-CB1–KO (n = 5–13) on SD. (I) 
Tissue NE levels in EF from Ati-CB1–WT 
(n = 8) and Ati-CB1–KO (n = 8) mice 
on SD. (J) Gene expression analysis 
(relative units) of thermogenic markers 
(Cox8b, Ucp1, Ppargc1a) in SF (n = 8–12). 
(K) Gene expression analysis (relative 
units) of thermogenic markers (Cox4i2, 
Ucp1) in BAT from Ati-CB1–WT (n = 8) 
and Ati-CB1–KO (n = 12) mice on SD. 
Data are shown as mean ± SEM.  
*P < 0.05; #P < 0.01; †P < 0.001 vs. WT, 
Student’s t test.
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cate that it is sufficient to abolish CB1 function in adi-
pocytes in order to induce body weight loss and reach 
a body weight and a metabolic profile similar to those 
observed under SD.
Genetic inactivation of adipocyte CB1 in Ati-CB1–
KO–TAO reduced obesity-related behavioral alterations. 
It is known that obesity causes behavioral changes in 
humans (50) and in rodents (51). On the other hand, 
the anti-obesity drug Acomplia (rimonabant, CB1 
inverse agonist) is associated with adverse effects such 
as anxiety and depression (52), similar to other weight 
loss therapies (53). Therefore, we analyzed obese- 
related anxiety-like phenotypes in Ati-CB1–KO–TAO 
using different behavioral paradigms. No significant 
differences were found in the total locomotion of Ati-
CB1–KO–TAO and WT in the open field (OF) (Supple-
mental Figure 12A). However, SHFD-fed Ati-CB1–WT–
TAO mice showed increased anxiety-like behavior in 
the elevated plus-maze (EPM), as indicated by the 
decreased percentage of entries into and time spent in 
the open arms of the maze. Conversely, in SHFD-fed 
Ati-CB1–KO–TAO mice, these parameters were com-
parable to those observed in SD (Supplemental Figure 
12, B and C). Anxiety-like states have been described 
in combination with decreased motivation for explor-
atory activity, which can be analyzed by using the 
holeboard (HB) test (54). SHFD decreased head dippings in Ati-
CB1–WT–TAO (Supplemental Figure 12D), whereas it showed no 
effect in Ati-CB1–KO–TAO. These data indicate that life-impair-
ing behaviors, such as the increased anxiety-like behavior often 
observed in obesity, can be reversed in Ati-CB1–KO–TAO SHFD 
mice, which showed behavior similar to that of SD-fed mice.
Discussion
The ability of adipocytes to expand upon excessive energy intake 
determines the overall capacity of the body’s energy reserve (55). 
We then tested the effect of AM6545 (10 mg/kg, i.p.), a periph-
eral CB1 antagonist (31, 32), on Ati-CB1–KO–TAO and Ati-CB1–
WT–TAO mice (Figure 5K). As compared with the corresponding 
vehicle groups, chronic treatment with the peripherally restricted 
CB1 blocker caused a strong reduction in body weight (Figure 5K) 
and a slight nonsignificant decrease in food intake in Ati-CB1–
WT–TAO mice (Supplemental Figure 11F), while having no effect 
in Ati-CB1–KO–TAO mice. Thus, the body weight of AM6545- 
treated Ati-CB1–WT–TAO became comparable to the body weight 
of Ati-CB1–KO–TAO mice (Figure 5K). Together, these data indi-
Figure 5. Adipocyte-specific CB1 deletion in obese mice 
mediates weight loss and reverses obesity-related meta-
bolic alterations. (A) Body weight growth curves of Ati-CB1–
WT–TAO (n = 8–10) and Ati-CB1–KO–TAO (n = 6–7) on both SD 
and SHFD before (weeks 4 to 16) and after (weeks 17 to 22) 
tamoxifen-induced CB1 deletion. (B) Body weight variation 
6 weeks after tamoxifen-induced CB1 deletion in mice on 
SHFD. (C) Fasting blood glucose in Ati-CB1–WT–TAO (n = 8) 
and Ati-CB1–KO–TAO (n = 8) on SHFD. (D–H) Plasma levels of 
insulin, leptin, adiponectin, PAI1, and IL-6 in Ati-CB1–WT–TAO 
(n = 4–9) and Ati-CB1–KO–TAO (n = 4–8) on SD and SHFD. (I) 
Glucose and insulin tolerance tests in Ati-CB1–WT–TAO (n = 
9) and Ati-CB1–KO–TAO (n = 10) on SHFD. (J) Gene expression 
for markers of alternatively activated macrophages (Mrc1, 
Clec10a) in EF and SF from Ati-CB1–WT–TAO (n = 7) and Ati-
CB1–KO–TAO (n = 5) on SHFD. (K) Chronic treatment with the 
peripherally acting CB1 antagonist AM6545 (10 mg/kg, i.p.) or 
its vehicle and analysis of body weight in Ati-CB1–WT–TAO  
(n = 8–7) and Ati-CB1–KO–TAO (n = 6) on SHFD. Data are 
shown as mean ± SEM. *P < 0.05; #P < 0.01; †P < 0.001, 2-way 
ANOVA, Bonferroni’s post hoc test (A, K, I); Student’s t test 
(B, C, J); 1-way ANOVA (D–H).
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pathetic terminals. WAT is also innervated, although to a lesser 
degree, suggesting that alternative pathways participate in the 
regulation of Ucp1 expression in WAT. Recent investigations sug-
gested that alternatively activated macrophages also contribute 
to BAT thermogenesis and browning of WAT by acting as a local 
source of catecholamines (14–17), but these are in contrast with 
other recent findings (18, 19). Here, we have demonstrated that 
ATMs express all enzymes necessary for catecholamine synthesis. 
In particular, we were able to detect expression of Th, the rate- 
limiting gene in NE production, in CD11b+F4/80+ adipose tissue 
cells using 2 independent experimental approaches, real-time PCR 
and the more sensitive ddPCR method. Both approaches showed 
very low gene expression levels, although TH protein levels were 
certainly measured in ATMs and M2 macrophages, as analyzed 
by flow cytometry. Confocal microscopy studies were not able to 
detect the presence of TH protein in CD206+ cells in adipose tis-
sue, similar to recent studies (18, 59), this inability likely related to 
the detections limits of immunohistochemistry techniques. At this 
point, we do not know the functional relevance of these marginal 
expression levels; nonetheless, biochemical studies of NE synthe-
sis in isolated ATMs should be able to shed light on this open issue.
Interestingly, double confocal microscope analysis showed 
that the CD206+ macrophage extensions are in tight anatomical 
proximity to TH+ sympathetic fibers, in agreement with recent 
findings (59). Due to this intimate proximity between M2 mac-
rophage projections and sympathetic nerve terminals, we cannot 
exclude that macrophages may release other signaling molecules 
able to increase NE output from the sympathetic nerves or, alter-
natively, that the M2 macrophages may take up NE from the sym-
pathetic cells and then release it. Wolf and colleagues (59) put 
forward the notion that certain macrophage subpopulations could 
modulate BAT sympathetic innervations via upregulation of Plex-
in4A. Indeed, there is rising and compelling evidence on the role 
of ATMs in adipose tissue remodeling and metabolic beneficial 
effects, via releasing NE and/or other factors or via other indepen-
dent mechanisms, such as lysosome biogenesis (14–16, 19, 59–62).
Animal housing temperature (22°C) has been described as 
a chronic thermal stress for rodents (47). Under these housing 
conditions, mice have to increase whole energy metabolism and 
food intake for maintenance of a constant body temperature (42). 
Therefore, we analyzed HFD-fed Ati-CB1–KO mice at thermoneu-
trality (30°C). Strikingly, Ati-CB1–KO mice fed at thermoneutrality 
showed body weight reduction comparable to that of Ati-CB1–KO 
mice at standard animal housing temperature (22°C). Important-
ly, upregulation of mitochondrial biogenesis regulators (Ppargc1a, 
Tfam) as well as of Ucp1 and mitochondrial genes, M2 markers 
(Clec10a, Mrc1), and NE synthesizing genes (Ddc), were increased 
in the SF of Ati-CB1–KO mice compared with control littermates at 
thermoneutral conditions. Thereby, considering that mice housed 
at 30°C lack the thermal drive to activate BAT thermogenesis or to 
beige WAT (63), our findings may support the notion that the M2 
macrophage polarization plays a prominent role in the lean pheno-
type observed in Ati-CB1–KO mice under HFD at thermoneutrality.
A pharmacological study has shown that the peripheral 
CB1 blockade using peripherally restricted CB1 inverse agonist 
JD5037 alleviates obesity by reversing leptin resistance in DIO 
mice (33). Genetic inactivation of adipocyte CB1 in Ati-CB1–KO–
Our work demonstrates that the loss of adipocyte CB1 affects 
energy balance by promoting a profound remodeling in depot- 
specific adipocyte functions. These changes were associated with 
increased alternative macrophage activation and enhanced sym-
pathetic outflow into adipose tissue.
These insights were obtained using a transgenic mouse line 
(AdipoqCreERT2) (35), allowing the specific and inducible inacti-
vation of the CB1 gene in adiponectin-positive cells, thereby over-
coming previously observed limitations using other transgenic 
mouse lines targeting adipocytes (56).
Adipose tissue plasticity has been studied extensively, and 
recent findings indicate a remarkable remodeling capacity of adi-
pocytes (10, 41, 57, 58). Here, adipocyte-specific CB1 deletion led 
to smaller adipocytes and decreased lipid storage in EF, in both 
SD and HFD. Thus, in agreement with previously published evi-
dence (40), CB1 is essential for the maintenance of the differen-
tiation state and lipid storage capacity of white adipocytes. The 
reduced energy storage capacity was linked to decreased body 
weight in Ati-CB1–KO mice. Although gene deletion was induced 
in mature adipocytes at the age of 4 to 5 weeks, at this point, we 
cannot exclude the possibility that CB1 function is also required 
for proper developmental processes, such as the expansion of adi-
pose tissue. In SF, we showed that CB1 deficiency in adipocytes 
led to an increase in the multilocular Ucp1-positive adipocytes. 
Gene expression analysis confirmed an upregulation of thermo-
genic genes and mitochondrial biogenesis in SF, suggesting the 
browning of this fat depot in Ati-CB1–KO mice. Furthermore, 
a similarly increased thermogenic program was found in BAT. 
Accordingly, energy dissipation was markedly enhanced in the 
Ati-CB1–KO mice under HFD. Altogether, CB1 inactivation in 
adipocytes was able to reduce lipid storage capacity, to increase 
the number of multilocular Ucp1-positive adipocytes in SF, and to 
induce BAT thermogenesis.
Ati-CB1–KO mice were leaner than Ati-CB1–WT controls inde-
pendently of the diet, and their daily caloric intake was reduced. 
However, as suggested by pair-feeding experiments, the decreased 
caloric intake seems to play a minor role in the lean metabolic phe-
notype of Ati-CB1–KO mice.
Strikingly, the reprogramming induced by adipocyte CB1 dele-
tion precedes the emergence of body weight changes. In particular, 
we observed a delayed differentiation of adipocytes in EF, adipose 
tissue browning in SF, and an increase in markers of mitochondrial 
activity in BAT. Independently of the emergence of body weight 
differences between genotypes, the thermogenic and metabol-
ic remodeling in Ati-CB1–KO adipose tissue can be linked to the 
increased local abundance of alternatively activated macrophages 
(M2 polarization). Concomitantly, we found increased expression 
of biosynthetic enzymes of NE together with enhanced NE con-
centrations in adipose tissue. In summary, loss of adipose CB1 is 
a primary cause for early changes in metabolic, biochemical, and 
morphological features of adipocytes, preceding the diet-induced 
whole body changes, and thus, these alterations in adipocytes are 
not mere consequences of many weeks of HFD feeding.
The classical model proposes that BAT thermogenesis and 
browning of WAT are mediated by enhanced NE release from 
sympathetic nerve terminals and stimulation of β-adrenergic 
receptors in adipose tissue. BAT is densely innervated by sym-
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protein, 45% carbohydrate; Dottori Piccioni Laboratory), or with an 
SHFD containing 21.1 kJ/g (caloric contribution: 60% fat, 17% protein, 
23% carbohydrate; Altromin, C1090/60).
Histology and immunofluorescence. Paraffin-embedded tissue was 
sectioned on a microtome (8 μm) and mounted on microscope glass 
(Thermo Scientific, Superfrost Plus, 4951PLUS). Sections were dep-
araffinized. For histology, sections were stained with hematoxylin (2 
g/l, Roth, CN04.1) for 15 minutes and with eosin (0.1%; in 0.0003% 
acetic acid) for 10 minutes. Cell size quantification was performed 
after H&E staining; sequential photographs from EF were taken and 
processed with ImageJ software (version 1.45, NIH). For immunoflu-
orescence, epitopes were unmasked by the use of heat treatment in 
sodium citrate buffer (10 mM) at 95°C for 15 minutes. Sections were 
preincubated with 5% BSA and incubated overnight at 4°C in a 1:50 
dilution of polyclonal anti-mouse CB1 antibody (rabbit L15 antiserum, 
directed against the last 15 amino acids of CB1; gift of Ken Mackie, 
Indiana University, Bloomington, Indiana, USA), in a 1:1,000 dilution 
of a monoclonal anti-mouse adiponectin antibody (Abcam, ab22554), 
or in a 1:1,000 dilution of a polyclonal anti-mouse UCP1 antibody 
(Santa Cruz Biotechnology Inc., sc-6529). Sections were incubated 
with the secondary antibody (1:1,000 coupled to Alexa Fluor 546 or 
Alexa Fluor 488, Invitrogen) for 2 hours at room temperature. For flu-
orescence microscopy, sections were analyzed using the Leica DMRA 
microscope (Leica Microsystems) equipped with appropriate exci-
tation and emission filters.
β-Galactosidase staining. Cre recombinase activity was evaluated 
by crossing the AdipoqCreERT2 mouse line with the Gt(ROSA)26Sor 
Cre reporter mouse line (35). β-Galactosidase staining was performed 
as described (65).
Electron microscopy. Ati-CB1–WT and Ati-CB1–KO on SD and HFD 
(n = 3/group) were deeply anesthetized with pentobarbital and transcar-
dially perfused with 2% glutaraldehyde in 0.1 M phosphate buffer pH 
7.4. Fat depots were collected and cut in small pieces and post-fixed for 
6 hours at 4°C in the same fixative. Small fragments of inguinal SF were 
fixed in 2% glutaraldehyde/2% paraformaldehyde in 0.1 M phosphate 
buffer (pH 7.4) for at least 4 hours, post-fixed in 1% osmium tetroxide 
and 1% potassium hexacyanoferrate (II), dehydrated in acetone, and 
epoxy resin embedded. Semi-thin sections (2 μm) were stained with 
toluidine blue, and thin sections obtained with an MT-X ultratome 
(RCM) were mounted on copper grids, stained with lead citrate, and 
examined with a CM10 transmission electron microscope (Philips).
Food intake, body weight monitoring, pair feeding. Mice had ad 
libitum access to food and water. Food intake and body weight were 
measured at 9 am, twice a week from 8 to 22 weeks of age. For the 
pair-feeding experiment, from week 12 to week 16, Ati-CB1–WT mice 
received a daily amount of food that was calculated by determining 
the daily food intake of the Ati-CBO–KO mice based on the weekly 
average consumption.
Indirect calorimetry. EE was assessed as described by measuring 
oxygen consumption (VO2) and carbon dioxide production (VCO2) by 
indirect calorimetry (46). Twelve-week-old male WT (n = 16) and Ati-
CB1–KO (n = 12) mice maintained on an HFD for 5 to 6 weeks were 
individually housed in metabolic chambers (TSE Systems GmbH) in 
which water and food intake, locomotor activity, and gas exchanges 
were monitored. Following 48 hours of acclimation, O2 consumption, 
CO2 production, locomotor activity, and food and water intake were 
measured every 15 minutes for 48 hours. Mice had ad libitum access to 
TAO mice reduced body weight and ameliorated obesity-related 
metabolic and behavioral alterations. Furthermore, treatment 
with AM6545, a restricted peripheral CB1 antagonist (31, 32), was 
unable to modify body weight and food intake in Ati-CB1–KO–
TAO mice, suggesting that the adipocyte CB1 plays a major role in 
the actions of this compound.
The present findings reveal a critical role for the adipocyte 
CB1 in the regulation of energy balance. The selective deletion of 
CB1 in adipocytes promotes profound reprogramming, not only of 
adipocytes, but also of adipocyte-resident cells, including alter-
natively activated macrophages that work concomitantly with 
sympathetic neuronal efferents to play a pivotal role in reducing 
adipocyte differentiation and browning WAT as well as promot-
ing a thermogenic program. Based on our current experimental 
approaches, we cannot estimate the contribution of alternatively 
activated macrophages in comparison with sympathetic innerva-
tion to the enhanced NE turnover observed in lean Ati-CB1–KO 
mice or determine whether the M2 macrophages are local sources 
of sufficient NE concentrations with physiological relevance. In 
summary, we conclude that deletion of CB1 in adipocytes leads to 
an increased SNS tone together with M2 macrophage abundance, 
both of which play critical roles in the emergence of the lean phe-
notype of Ati-CB1-KO. This compelling evidence illustrates the 
crosstalk between adipocytes and immune cells in concert with 
the SNS, in which CB1 occupies a key regulatory function.
Methods
Mice. Male Total-CB1–KO (also named CB1–/–) mice were generated 
and genotyped as described (64). Ati-CB1–KO mice (CB1 deletion in 
adipocytes; CB1fl/fl;AdipoqCreERT2tg /+ with tamoxifen treatment) were gen-
erated by crossing the AdipoqCreERT2 line (35) with mice contain-
ing the 2 loxP sites flanking the open reading frame of the CB1 gene 
(64). Mice were genotyped by PCR as previously described (34, 35). 
For the AdipoqCreERT2 line, the primers 5′-TGGTGCATCTGAAG-
ACACTACA and 5′-TGCTGTTGGATGGTCTTCACAG gave a band 
of 600 bp, when the transgene was present. For the genotyping of 
the CB1 gene locus, 3 primers were used: G50 (5′-GCTGTCTCTG-
GTCCTCTTAAA), G51 (5′-GGTGTCACCTCTGAAAACAGA), and 
G53 (5′-CTCCTGTATGCCATAGCTCTT). G50 plus G51 detected the 
floxed CB1 allele as a 500-bp band and the WT CB1 allele as a 400-bp 
band, G50 plus G53 detected the floxed CB1 allele after recombina-
tion (i.e., the inactivated CB1 gene) as a 600-bp band. Mutant animals 
were on a mixed genetic background with a predominant C57BL/6N 
contribution (at least 9 backcrosses). Mice were housed under con-
ditions of controlled temperature (22°C) and illumination (12-hour 
light/12-hour dark cycle, light off at 7 pm). Generally, 4- to 5-week-old 
male Ati-CB1–KO mice and their littermate controls (CB1fl/fl, named 
Ati-CB1–WT) received tamoxifen (1 mg/mouse, stock solution in 33% 
ethanol, 33% dimethyl sulfoxide, 33% Tween-80, finally diluted 1:10 
in 0.15 M NaCl; tamoxifen from Sigma-Aldrich, T5648) once a day i.p. 
for 5 consecutive days. For experiments shown in Figure 5, tamoxifen 
treatment was performed at 16 weeks of age. When treatment was at 
week 4, 2 weeks after the last tamoxifen injection, animals were sin-
gle housed and sorted into their corresponding diet-specific group. 
Animals were fed with an SD containing 13.9 kJ/g (caloric contribu-
tion: 11% fat, 36% protein, 53% carbohydrate; Altromin, C1090/10), 
with an HFD containing 18.9 kJ/g (caloric contribution: 40% fat, 15% 
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In vivo quantification of adipose tissue. Ati-CB1–WT (n = 6–12) and 
KO (n = 7–4) mice were placed under deep anesthesia with 5% sevoflu-
rane and oxygen supplementation (1 l/min) and scanned using an in 
vivo micro-CT scanner (eXplore Locus) at an isometric resolution of 
90 μm, as previously described (21).
Flow cytometric analysis and sorting of ATMs. Adipose tissues were 
minced and digested with collagenase II (1 mg/ml, Sigma-Aldrich) 
for 30 minutes at 37°C on a shaker. The digested cell suspension was 
passed through a 70-μm strainer (MACS, Miltenyi Biotec) and centri-
fuged at 700 g for 10 minutes at 4°C to isolate the stromal-vascular 
fraction. Pelleted cells were resuspended in rbc lysis buffer (155 mM 
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 5 minutes and diluted with 
FACS buffer (PBS containing 1% FCS and 2 mM EDTA) to neutralize 
rbc lysis. Samples were centrifuged at 700 g for 10 minutes at 4°C and 
resuspended in FACS buffer. Antibodies against mouse CD206-PE 
(BioLegend, C068C2), CD301-APC (BioLegend, LOM-14), F4/80-
APC (BioLegend, BM8), CD11b-FITC (Abcam, ab24874), and TH-PE 
(Abcam, ab209921) were used for flow cytometric analysis (acquired 
on LSRFortessa, BD, additionally equipped with a yellow-green laser 
for detecting PE and analyzed with FlowJo software, TreeStar). Sorting 
of ATMs (FACS Aria II SORP using DiVa software, BD) was based on 
anti-mouse CD11b-PE (BioLegend, M1/70) and anti-mouse F4/80-
APC antibody (BioLegend, BM8). Samples were fixed in 4% PFA for 15 
minutes at 4°C before staining of intracellular antigens. FACS-sorted 
CD11b+F4/80+ ATMs were directly resuspended in 750 μl of TRIzol 
Reagent (Thermo Fisher) for total RNA isolation.
ddPCR system. Before droplet generation, ddPCR reactions 
were prepared in a manner similar to that of real-time reactions 
using TaqMan probes labeled with FAM (2× ddPCR Mastermix [Bio-
Rad], 20× TaqMan probes and template in a final volume of 20 μl). 
As template, the maximum input (9 μl) from undiluted cDNA of 
CD11b+F4/80+-sorted ATMs were loaded per ddPCR reaction. Posi-
tive controls (1 μl from 1:1,000 dilution of cDNA from adrenal gland; 
and 1 μl from 1:100 dilution of cDNA from brain stem) and nega-
tive controls (1 μl from 1:1,000 dilution of no-RT adrenal gland; and 
9 μl of H2O as no template control) were included. Each assembled 
ddPCR reaction mixture was applied into a sample droplet well of an 
8-channel disposable droplet generator cartridge (Bio-Rad), and 70 μl 
of droplet generator oil (Bio-Rad) was loaded into an oil well for each 
channel. The cartridge was placed into the droplet generator (Bio-Rad) 
and 1 nl monodisperse droplets were formed in around 2 minutes, 
generating 15,000 droplets per sample. Droplets were transferred to 
a 96-well PCR plate, and droplet PCR amplification to end-point was 
performed in a conventional thermal cycler (95°C for 10 minutes; 40 
cycles of 95°C for 30 seconds and 60°C for 1 minute; followed by 98°C 
for 10 minutes and hold at 4°C). After PCR, the 96-well plate was load-
ed and analyzed by a 2-color detector droplet reader (Bio-Rad), which 
automatically assigns droplets as positive or negative based on their 
fluorescence amplitude. Analysis of the ddPCR data was performed 
with QuantaSoft analysis software (Bio-Rad).
Peroxidase immunohistochemistry. Immunohistochemistry was 
performed on 3-μm–thick paraffin-embedded sections of fat depots. 
In brief, paraffin sections were reacted with 0.3% H2O2 (in water; 10 
minutes) to block endogenous peroxidase, rinsed with PBS, and incu-
bated in a 3% normal-serum blocking solution for 60 minutes. Then 
they were incubated with the anti-TH primary antibody (1: 400, Milli-
pore, AB1542) overnight at 4°C. After rinse in PBS, sections were incu-
HFD and water throughout the study. The values of EE corresponding 
to the lowest 10 values of ambulatory activity over the 48-hour mea-
surement were averaged to provide a measure of REE (kcal/h). EE and 
REE were analyzed by ANCOVA using body weight as covariate.
RNA isolation and real-time PCR analysis. RNA was isolated from 
Ati-CB1–WT and Ati-CB1–KO mice on SD and HFD and analyzed 
as described (24). Tissues were homogenized in TRIzol (Sigma- 
Aldrich, 12183-555), aqueous phase was collected, and RNA was 
isolated by using a QIAGEN RNA Kit (QIAGEN, 74106). For 
CD11b+F4/80+ FACS-sorted ATMs, RNA was isolated using a RNeasy 
Plus Micro Kit (QIAGEN, 74034). cDNA was synthesized by using a 
High Capacity RNA-to-cDNA Kit (Applied Biosystems, 4390778). 
Primers for TaqMan Gene Expression Assay were purchased from 
Applied Biosystems. Real-time PCR analysis was carried out with 
the following primers (showing gene name followed by probe 
code): Pparg: Mm01184323_m1; Cebpa: Mm00514283_s1; Adipoq: 
Mm00456425_m1; Lep: Mm00434759_m1; Fasn: Mm00662291_g1; 
Acaca: Mm01304257_m1; Ucp1: Mm01244861_m1; Ppargc1a: 
Mm01208832_m1; CB1: Mm00432621_s1; Elovl3: Mm00468164_
m1; Dio2:Mm00515664_m1; Cox8b: Mm00432648_m1; Cox4i2: 
Mm00446387_m1; Tfam: Mm00447485_m1; Adrb3: Mm02601819_
g1; Pomc: Mm00435874_m1; Npy: Mm01410146_m1; Cartpt: 
Mm04210469_m1; Pmch: Mm01242886_g1; Socs3: Mm00545913_
s1; Mrc1: Mm00485148_m1; Clec10a: Mm00546125_g1; Th: 
Mm00447557_m1; Dbh: Mm00460472_m1; Ddc: Mm00516688_m1; 
and Gusb: Mm01197698_m1.
Hormone and metabolite assays. Plasma leptin, insulin, IL-6, and 
PAI1 were measured by Mouse Serum Adipokine Kit (Milliplex Map, 
Millipore, MADPK-71K), adiponectin by Mouse Adiponectin ELISA 
Assay Kit (Biovision, K4902-100), plasma free fatty acids by Fatty 
Acid Kit (Biovision, K612-100), plasma total cholesterol and LDL by 
HDL and LDL Cholesterol Quantification Kit (BioVision, K631-100), 
plasma and hepatic triglycerides by Triglyceride Quantification Kit 
(Biovision, K622-100), and blood glucose levels by an automated 
blood glucose reader (OneTouch Ultra2 Glucometer) (66).
NE turnover. Ati-CB1–KO mice and their WT littermates on HFD 
were divided into 2 groups to study the NE turnover in EF, SF, and 
BAT at time point zero and 3 hours after i.p. injection of the TH inhib-
itor methyl ester of α-methyl-P-tyrosine (80 mg/kg, Sigma-Aldrich, 
M8131). EF, SF, and BAT were then rapidly removed and stored at 
–80°C for subsequent NE quantification. Tissue NE was measured by 
LDN ELISA Kit (Labor Diagnostika Nord, BA E-5200). NE turnover 
was calculated by plotting tissue NE content semilogarithmically, and 
the slope of the declining endogenous NE level versus time was used 
to calculate the turnover rate (67). Rates of NE turnover were then 
calculated by multiplying the turnover rate for each NE content of the 
organs of the individual mouse.
Glucose and insulin tolerance tests. For glucose tolerance test, over-
night-fasted mice were given i.p. glucose (2 mg/g). For insulin toler-
ance test, overnight-fasted mice were injected with insulin (0.75 IU/kg 
i.p.; Eli Lilly). Tail blood glucose was determined at defined time inter-
vals (OneTouch Ultra, LifeScan). Concerning insulin tolerance tests, 
due to increased total adiponectin levels in Ati-CB1–KO mice and the 
insulin sensitization effect of this hormone on peripheral organs (36), 
we used a low insulin dose (0.5 IU/kg). Preliminary experiments with 
Ati-CB1–KO mice revealed that commonly used insulin doses induced 
severe hypoglycemia in KO mice.
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Endocannabinoid measurements by LC–tandem mass spectrometry. 
Plasma samples from Ati-CB1–WT mice on SD (n = 7), Ati-CB1–WT 
mice on HFD (n = 12), Ati-CB1–KO mice on SD (n = 6), and Ati-CB1–
KO mice on HFD (n = 4) were stored at –80°C until extraction. Samples 
were allowed to thaw on ice water, and 50 μl aliquots were transferred 
to 1.5 ml centrifugation tubes. After adding 300 μl of ice-cold ethyl 
acetate/hexane (9:1, v/v) containing the deuterated endocannabinoids 
as internal standards, tubes were vortexed for 30 seconds with Vor-
tex Disruptor (Scientific Industries). Tubes were immediately centri-
fuged for 15 minutes at 16,000 g at 4°C. The upper organic phase was 
removed, evaporated to dryness under a gentle stream of nitrogen at 
37°C, and reconstituted in 50 μl acetonitrile. Concentrations of AEA 
and 2-arachidonoylglycerol (2-AG) were determined by liquid chroma-
tography (LC) multiple reaction monitoring (MRM). LC and MRM con-
ditions were as described (69). AEA and 2-AG levels were normalized 
to plasma volume.
Pharmacological treatment with peripheral CB1 antagonist. Ati-
CB1–KO–TAO and Ati-CB1–WT–TAO mice on HFD were injected 
i.p. with AM6545 (10 mg/kg), a neutral peripherally restricted CB1 
antagonist (31, 32), or with vehicle for 3 weeks starting at 5 weeks 
after tamoxifen injection.
Behavioral experiments. EPM and HB experiments were performed 
as previously described (54). Ati-CB1–WT–TAO (n = 8–10) and Ati-
CB1–KO–TAO (n = 6–7) mice were analyzed.
Statistics. Results are expressed as mean ± SEM. Data were ana-
lyzed by unpaired 2-tailed Student’s t test or by ANOVA followed by 
appropriate post hoc tests. Data with repeated measurements were 
analyzed by repeated-measures ANOVA followed by post-hoc test. 
Statistical comparison of NE turnover was made with Student’s t test. 
To determine whether differences in EE and REE were attributable 
simply to differences in body weight, ANCOVA was performed using 
as covariates appropriate measures of body weight. All the statistical 
analyses were performed by using GraphPad Prism 5.0 software. P < 
0.05 was considered statistically significant.
Study approval. Experimental protocols were carried out in accor-
dance with the Council Directive 2010/63EU of the European Par-
liament and the Council of 22 September 2010 on the protection of 
animals used for scientific purposes and approved by the local ethical 
committees on animal care and use in Rhineland-Palatinate, Germany 
(reference number 23 177-07/G 10-1-038, and 23 177-07/G 16-1-005), 
by the French Ministry of Agriculture and Fisheries (animal experi-
mentation authorization 3309004), by the ethical committee of the 
University of Bordeaux (N° 5012062-A), and by University of Bologna, 
Local Ethical Committee and Italian Ministry of Health (Project ID 
09/59/09, and Project ID 54464-X/10).
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